(Sharecast News) - Convatec underwhelmed the market with its new 'Accelerate' strategy on Thursday as shares fell after the medical products and technology company unveiled plans on how it expects to deliver 6-8% annual organic revenue growth over the medium term.
Accelerate follows on from Convatec's previous FISBE strategy, which the...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE